Pharmaceuticals: Restrictions in Use and Availability
(2001; 40 pages) View the PDF document
Table of Contents
Open this folder and view contentsIntroduction
Close this folderMonocomponent products
View the documentAlatrofloxacin mesilate
View the documentAldesleukin
View the documentAmineptine
View the documentAmfepramone hydrochloride
View the documentAristolochia
View the documentAstemizole
View the documentBromfenac
View the documentBuprenorphine
View the documentBuspirone hydrochloride
View the documentCamphor
View the documentChlormezanone
View the documentCisapride
View the documentDantron
View the documentDequalinium
View the documentDexfenfluramine hydrochloride
View the documentDiphenoxylate
View the documentDoxycycline hydrochloride (capsules)
View the documentDronabinol
View the documentEbrotidine
View the documentEpoetin alfa and epoetin beta
View the documentErythrityl tetranitrate
View the documentFenfluramine
View the documentFlunitrazepam
View the documentFurazolidone
View the documentGentamicin (topical preparations)
View the documentGrepafloxacin hydrochloride
View the documentGinkgo biloba
View the documentKetamine hydrochloride
View the documentKetorolac
View the documentLamivudine
View the documentLevamisole hydrochloride
View the documentLexipafant
View the documentLoxoprofen sodium
View the documentMedifoxamine
View the documentMepacrine
View the documentMetamizole sodium
View the documentMethylrosanilinium chloride
View the documentMetoclopramide (paediatric)
View the documentMibefradil
View the documentMisoprostol
View the documentNandrolone
View the documentOxeladin citrate
View the documentPexiganan
View the documentPhenolphthalein
View the documentPhentermine
View the documentPhentolamine mesilate
View the documentPhenylbutazone
View the documentPiperazine
View the documentPromethazine
View the documentProxibarbal
View the documentPyrithione zinc
View the documentPumactant
View the documentRituximab
View the documentSertindole
View the documentSibutramine
View the documentSulfaguanidine
View the documentTerfenadine
View the documentTilbroquinol
View the documentTolcapone
View the documentTramadol
View the documentTroglitazone
View the documentTrovafloxacin mesilate
View the documentZopiclone
Open this folder and view contentsCombination Products
Open this folder and view contentsGroup Products
 

Tilbroquinol

Product name:

Tilbroquinol

CAS number:

7175-09-9

Synonyms:

7-Bromo-5-methyl-8-quinolinol

Country

Effective Date

Description of action taken
Grounds for decision

France

1999

The Agence du Médicament has withdrawn the antiprotozoal, tilbroquinol from the market because the hepatoxicity of the drug outweighs the potential benefit. (Reference: Décision de retrait de l'autorisation de mise sur le marché d'Intetrix P granulés, du 5 juillet 1999.)

Morocco

November 1997

The Direction du médicament et de la pharmacie has suspended marketing authorization for the paediatric formulation of tilbroquinol and the therapeutic indications for the adult formulation were restricted to the treatment of intestinal amoebiasis. (Reference: Letter from the Direction du médicament et de la pharmacie, Rabat, 8 September 2000.)

Saudi Arabia

June 1999

The Ministry of Health has withdrawn from the market products containing tilbroquinol and a combination product containing tilbroquinol/tiliquinol because of a risk of hepatotoxicity associated with their use. (Reference: Communication from the WHO Regional Office for the Eastern Mediterranean enclosing a notification from the Ministry of Health, Saudi Arabia, 20 June 1999.)

to previous section
to next section
 
 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: November 5, 2014